Gå direkt till huvudinnehållet

Polycystisk njursjukdom

Senast uppdaterad: Publicerad:
Sakkunnig:


  1. Arbejdsgruppe nedsat af Dansk Nefrologisk Selskab. Autosomal dominant polycystisk nyresygdom. Forslag til retningslinjer for patienter og disses slægtninge. Ugeskr Læger 2004; 166: 3807-11. PubMed  
  2. Bajwa ZH, Gupta S, Warfield CA, Steinman TI. Pain management in polycystic kidney disease. Kidney Int 2001; 60: 1631-44. PubMed  
  3. Bajwa ZH, Sial KA, Malik AB, Steinman TI. Pain patterns in patients with polycystic kidney disease. Kidney Int 2004; 66: 1561-9. PubMed  
  4. Chapman AB. Cystic disease in women: clinical characteristics and medical management. Adv Ren Replace Ther 2003; 10: 24-30. PubMed  
  5. Grantham JJ, Chapman AB, Torres VE. Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes. Clin J Am Soc Nephrol 2006; 1: 148-57. PubMed  
  6. Grantham JJ, Torres VE, Chapman AB, et al. Volume progression in polycystic kidney disease. N Engl J Med 2006; 354: 2122-30. PubMed  
  7. Gabow PA. Autosomal dominant polycystic kidney disease. N Engl J Med 1993; 329: 332-42. New England Journal of Medicine  
  8. Fick GM, Gabow PA. Natural history of autosomal dominant polycystic kidney disease. Annu Rev Med 1994; 45: 23-9. PubMed  
  9. Demetriou K, Tziakouri C, Anninou Ket al. Autosomal dominant polycystic kidney disease - type 2. Ultrasound, genetic and clinical correlations. Nephrol Dial Transpl 2000; 15: 205-11. PubMed  
  10. Nicolau C, Torra R, Badenas C et al. Autosomal dominant polycystic kidney disease type 1 and 2: assessment of US sensitivity for diagnosis. Radiology 1999; 213: 273-6. Radiology  
  11. Fick-Brosnahan G, Johnson AM, Strain JD, Gabow PA. Renal asymmetry in children with autosomal dominant polycystic kidney disease. Am J Kidney Dis 1999; 34: 639-45. PubMed  
  12. Sunde L, Schwartz M, et al. Autosomal dominant polycystisk nyresygdom. Ugeskr Læger 2004; 166: 3807-11. Ugeskrift for Læger  
  13. Perrone R. Imaging progression in polycystic kidney disease. N Engl J Med 2006; 354: 2181-3. PubMed  
  14. Torres VE, Harris PC. Mechanisms of disease: autosomal dominant and recessive polycystic kidney diseases. Nat Clin Pract Nephrol 2006; 2: 40-55. PubMed  
  15. Tao Y, Kim J, Schrier RW, Edelstein CL. Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease. J Am Soc Nephrol 2005; 16: 46-51. PubMed  
  16. Ruggenenti P, Remuzzi A, Ondei P, et al. Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease. Kidney Int 2005; 68: 206-16. PubMed  
  17. Ecder T, Schrier RW. Hypertension in autosomal-dominant polycystic kidney disease: early occurrence and unique aspects. J Am Soc Nephrol 2001; 12: 194-200. PubMed  
  18. Torres VE, Wang X, Qian Q, Somlo S, Harris PC, Gattone VH II. Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nat Med 2004; 10: 363-4. PubMed  
  19. Ruggenenti P, Remuzzi A, Ondei P, et al. Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease. Kidney Int 2005; 68: 206-16. PubMed  
  20. Shillingford JM, Murcia NS, Larson CH, et al. The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc Natl Acad Sci U S A 2006; 103: 5466-71. PubMed  
  21. Wüthrich RP, Mei C. Pharmacological management of polycystic kidney disease. Expert Opin Pharmacother 2014; 15: 1085-95. doi:10.1517/14656566.2014.903923 DOI  
  22. Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 2012; 367: 2407-18. doi:10.1056/NEJMoa1205511 DOI  
  23. Schrier RW. Optimal care of autosomal dominant polycystic kidney disease patients. Nephrology (Carlton). 2006; 11: 124-30. PubMed  
  24. Gabow PA, Johnson AM, Kaehny WD, Kimberling WJ, Lezotte DC, Duley IT et al. Factors affecting the progression of renal disease in autosomal dominant polycystic kidney disease. Kidney Int 1992; 45: 1311-9. PubMed  
  25. Schievink WI. Genetics of intracranial aneurysms. Neurosurgery 1997; 40: 651-63. PubMed  
  26. Ronkainen A, Hernesniemi I, Puranen M et al. Familial intrakraniel aneurysms. Lancet 1997; 349: 380-4. PubMed  
  27. Butler WE, Barker FG, Crowell RM. Patients with polycystic kidney disease would benefit from routine magnetic resonance angiographic screening for intracerebral aneurysms: A decision analysis. Neurosurgery 1996; 38: 506-16. PubMed  
  • Nils Grefberg, med dr och överläkare internmedicin och nefrologi, tidigare vid Medicinkliniken, Centrallasarettet Växjö

Tidigare sakkunniga

  • Tor Erik Widerøe, professor, Norges teknisk-naturvitenskapelige universitet och överläkare vid Seksjon for nyresykdommer, St. Olavs Hospital, Trondheim
  • Terje Johannessen, professor i allmänmedicin, Institutt for samfunnsmedisinske fag, Norges teknisk-naturvitenskapelige universitet, Trondheim